Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

BACKGROUND. Regorafenib at the standard intermittent dosing schedule proved effective in the GRID trial for refractory gastrointestinal stromal tumors (GISTs). However, this dosing schedule requires frequent dose reduction, and the progression of GISTs or tumor‐related symptoms during the off‐treatm...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Kim, Jae‐Joon, Ryu, Min‐Hee, Yoo, Changhoon, Beck, Mo Youl, Ma, Jung Eun, Kang, Yoon‐Koo
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2019
Fag:
Sarcomas
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853125/
https://ncbi.nlm.nih.gov/pubmed/31036770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0033
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker